logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Panacea Biotec Ltd

Panacea Biotec

Small Cap•1,936 Employees•IPO 1995
Current Price
₹353.75
19.85 (5.94%)Updated
NSE :PANACEABIO
BSE :531349
Sector :Biotechnology
Today's Range
₹333.90
₹353.75
union icon
₹358.70
52 Week Range
52W Low₹305.05
52W High₹581.90
₹353.75
union icon
Downside15.96%
Upside64.49%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹2,217.89 Cr
Market Cap
Total market value of company
P/E Ratio
-
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
3.02
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹-1.18
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
-1.90%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
-4.57%
ROCE
Return on Capital Employed. >15% is good
Net Margin
-1.20%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
0.55%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
44.00%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
74.80%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.03
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹136.29
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
72.50%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • •Panacea Biotec boasts a substantial promoter holding of 72.48% as of March 2025, indicating significant insider confidence and a reduced risk of hostile takeovers. This high promoter stake suggests a strong alignment of interests between management and shareholders.
  • •Despite recent quarterly profit volatility, the company shows a relatively low debt-to-equity ratio of 0.03, suggesting a healthy financial structure and lower risk of financial distress compared to higher-debt peers in the pharmaceutical sector.

Weaknesses

5 points
  • •The company's Return on Equity (ROE) stands at -4.92%, indicating that the company is not generating returns for its shareholders. This negative ROE is a major concern and needs to be addressed for long-term investor confidence.
  • •Panacea Biotec reported a negative quarterly profit after tax of -4.67 Cr and an overall profit after tax of -27.2 Cr, highlighting significant profitability challenges. This indicates a struggle to convert sales into sustainable earnings.

Opportunities

3 points
  • •The global pharmaceuticals market is projected for steady growth, driven by an aging population and increasing healthcare spending. This trend offers Panacea Biotec a favorable environment for expanding its product portfolio and market reach.
  • •Investment in research and development for new drug formulations and vaccines could unlock significant growth avenues. Diversifying the product pipeline into high-demand therapeutic areas can enhance market share and revenue streams.

Threats

4 points
  • •The pharmaceutical sector faces intense competition from established players and new entrants, potentially leading to pricing pressures and reduced market share for Panacea Biotec. This competitive landscape could impact profitability.
  • •Strict and evolving regulatory policies, including drug approval processes and pricing controls, pose a significant threat. Non-compliance or adverse policy changes could lead to delays, fines, or market access restrictions for products.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Sandeep Jain
19 Dec 202420 Dec 202493.82 L
5,000
₹450.89SELL
Sandeep Jain
18 Dec 202420 Dec 202493.87 L
5,700
₹455.32SELL
Sandeep Jain
24 Dec 202425 Dec 202493.67 L
5,000
₹426.23SELL
Sandeep Jain
23 Dec 202425 Dec 202493.72 L
10,000
₹439.55SELL
Rajesh Jain
26 Dec 202430 Dec 20243,000
3,000
₹454.9BUY
Sandeep Jain
30 Dec 202431 Dec 202493.57 L
10,000
₹425.04SELL
Sandeep Jain
31 Dec 202402 Jan 202593.52 L
5,000
₹409.07SELL

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹413.27+₹59.52+16.82%
R3₹388.47+₹34.72+9.81%
R2₹373.58+₹19.83+5.61%
R1₹363.67+₹9.92+2.80%
PIVOT₹348.78-4.97-1.40%
CURRENT₹353.75--
S1₹289.27-₹64.48-18.23%
S2₹314.07-₹39.68-11.22%
S3₹323.98-₹29.77-8.41%
S4₹338.87-₹14.88-4.21%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
3.40L
(10 Mar 2026)
+213.4% vs avg
Delivery %
48.5%
(10 Mar 2026)
+3.0% vs avg
Avg Volume (20D)
1.09L
(10 Feb - 10 Mar)
20-day average
Avg Delivery %
45.6%
(10 Feb - 10 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Biocon Ltd
61,453.63 ₹ Cr
Best Profit Growth
Hester Biosciences Ltd
159.00 %
Highest Dividend Yield
Hester Biosciences Ltd
0.45 %

Peer Comparison

Company Name
BIOCON
Biocon Ltd
HESTERBIO
Hester Biosciences Ltd

About

PANACEABIO

Panacea Biotec Ltd

Panacea Biotec Limited is a multinational biotechnology company headquartered in New Delhi, India, established in 1984. Its core business focuses on the research, development, manufacturing, and marketing of a diverse range of healthcare products across various sectors. This encompasses a substantial portfolio spanning vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products, showcasing a vertically integrated approach to the healthcare market.

The company operates through two primary segments: Vaccines and Formulations. The Vaccines segment includes a wide array of vaccines targeting various diseases such as typhoid, pneumococcal infections, dengue fever, hepatitis A, and varicella (chickenpox). They also hold significant partnerships, such as their collaboration with the Russian Direct Investment Fund for the production of the Sputnik V COVID-19 vaccine. This demonstrates their capacity for large-scale vaccine production and global collaborations.

The Formulations segment encompasses a broad spectrum of prescription pharmaceuticals. These medications address a wide array of therapeutic areas including transplantation, renal disease, oncology, respiratory illnesses, pain management, diabetes, cardiovascular diseases, gastrointestinal issues, nephrology, osteoporosis, and orthopedics. This diversified portfolio demonstrates their commitment to providing treatment options across a wide range of medical needs.

Beyond pharmaceuticals and vaccines, Panacea Biotec also manufactures and markets nutraceuticals and pediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. This expansion into the health supplement and nutritional market showcases a strategic move to cater to broader health and wellness needs.

The company's international reach is significant, with exports to approximately 50 countries. Furthermore, Panacea Biotec has established key collaborations with various entities including Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for the manufacture and supply of Azacitidine injection, and the Indian Council of Medical Research for clinical trials of the DengiAll vaccine. This highlights their involvement in both international and domestic research and development collaborations.

In addition to its core healthcare businesses, Panacea Biotec also participates in the real estate sector, though the extent of this involvement is not specified in the provided information. Overall, Panacea Biotec presents a multifaceted biotechnology company with a strong presence in India and a growing international footprint, focusing on a diverse array of healthcare solutions.

COMPANY FACTS - PANACEABIO

Registered Address

B-1 Extn./G-3,, Mohan Co-operative Industrial Estate, Mathura Road

New Delhi

DELHI

IN

Tel: 911141679000

Website:https://www.panaceabiotec.com/

Investor Relations:http://www.panaceabiotec.com/en/section/investor-zone
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Biotechnology

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 1,936

IPO Date: 25/09/1995

MANAGEMENT - PANACEABIO

Dr. Rajesh Jain

Executive Chairman of the Board, Managing Director

Mr. Vinod Goel

Group Chief Financial Officer, Compliance Officer, Company Secretary, Head - Legal

Mr. Devender Gupta

Chief Financial Officer, Head - Information Technology

Mr. Sandeep Jain

Joint Managing Director, Executive Director

Mr. Ankesh Jain

Executive Director, Director - Sales and Marketing

Mr. Narotam Juneja

Additional Non Executive Non-Independent Director

Mr. Mukul Gupta

Non-Executive Independent Director

Mr. Rajesh Jain

Non-Executive Independent Director

Ms. Ambika Sharma

Additional Non-Executive Independent Director

Mrs. Manjula Upadhyay

Non-Executive Independent Director

Investor Questions Answered

Panacea Biotec Ltd (PANACEABIO) Stock FAQs

Get answers to the most common questions about Panacea Biotec Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Panacea Biotec Ltd (PANACEABIO) is ₹353.75. Today, the stock has gained by ₹19.85 (5.94%), trading in a range of ₹333.9 to ₹358.7. The stock opened at ₹333.9 with a trading volume of 3,40,356 shares.
Panacea Biotec Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,217.89 crores, P/E ratio of 0.00, ROE of -1.90%, and ROCE of -4.57%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Panacea Biotec Ltd (PANACEABIO) is ₹581.9, while the 52-week low is ₹305.05. Currently trading at ₹353.75, the stock is 17.6% away from its 52-week low and 39.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Panacea Biotec Ltd stock at ₹353.75 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of N/A. Today's performance shows a gain of 5.94%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Panacea Biotec Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹353.75, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Panacea Biotec Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: N/A, ROE: -1.90%, ROCE: -4.57%, Dividend Yield: 0.00%, EPS: ₹-1.18, Book Value: ₹136.29, Debt-to-Equity: 0.03, and Current Ratio: N/A. The company's market cap stands at ₹2,217.89 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Panacea Biotec Ltd stock opened at ₹333.9 and is currently trading at ₹353.75, showing a gain of ₹19.85 (5.94%). The intraday high is ₹358.7 and low is ₹333.9. The trading volume stands at 3,40,356 shares, indicating moderate market participation today.
Panacea Biotec Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-1.18, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
Panacea Biotec Ltd has a market capitalization of ₹2,217.89 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹353.75) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Panacea Biotec Ltd has a book value of ₹136.29 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹353.75, which is 159.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Panacea Biotec Ltd has a Return on Equity (ROE) of -1.90% and Return on Capital Employed (ROCE) of -4.57%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Panacea Biotec Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Panacea Biotec Ltd has a debt-to-equity ratio of 0.03, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Panacea Biotec Ltd has an Earnings Per Share (EPS) of ₹-1.18, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹353.75 and P/E ratio of 0.00, investors are paying 0.00 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Panacea Biotec Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Panacea Biotec Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Panacea Biotec Ltd stock, consider: 1) Fundamental Analysis - Review P/E (0.00), ROE (-1.90%), debt-to-equity (0.03), and growth rates. 2) Technical Analysis - Check 52-week range (₹305.05 - ₹581.90), moving averages, and chart patterns. 3) Valuation - Compare current price (₹353.75) with book value (₹136.29) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Panacea Biotec Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹353.75 is 35275x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Panacea Biotec Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹305.05 - ₹581.90). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.03 indicates leverage. 4) Liquidity Risk - Based on trading volume of 3,40,356 shares. 5) Valuation Risk - P/E of 0.00 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Panacea Biotec Ltd operates in the industry with key metrics: P/E ratio of 0.00, ROE of -1.90%, market cap of ₹2,217.89 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.03), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Panacea Biotec Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹353.75, with a 52-week range of ₹305.05 to ₹581.90. Based on fundamentals like P/E (0.00), ROE (-1.90%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Panacea Biotec Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹353.75. 2) Fundamental Deterioration - Declining ROE (currently -1.90%), increasing debt (D/E: 0.03), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Panacea Biotec Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.